Protocol Ledger

NCT06713837 · Phase III · RECRUITING

IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Interventional Phase III clinical trial protocol NCT06713837 sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-27 Enrollment: 339 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06713837
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)339 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06713837
Protocol FieldVerified Registry Value
NCT IdentifierNCT06713837
Consolidated Lead SponsorIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment339 participants (ESTIMATED)
Registered Start Date2025-02-27
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI